Abl Bio, Inc.
Clinical trials sponsored by Abl Bio, Inc., explained in plain language.
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called ABL103 in people with advanced solid tumors that have not responded to standard treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The study will enroll 96 participants to evalu…
Phase: PHASE1 • Sponsor: ABL Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New antibody combo aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug called ABL103, given together with the approved immunotherapy pembrolizumab (Keytruda) and sometimes a chemotherapy called taxane. The study includes 65 adults with advanced or metastatic solid tumors that have worsened af…
Phase: PHASE1, PHASE2 • Sponsor: ABL Bio, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:37 UTC